{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6793","upperLimit":"0.8540","value":"0.7667"},{"groupId":"OG001","lowerLimit":"0.6847","upperLimit":"0.8846","value":"0.7846"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at \\> 4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMC-A12 + Multi-agent intensive chemotherapy regimen.","id":"OG000","title":"IMC-A12"},{"description":"Add temozolomide to vincristine/irinotecan cycles.","id":"OG001","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"20 participants were excluded because of ineligibility or absence in overall response evaluation.","reportingStatus":"POSTED","timeFrame":"From the start of treatment until a maximum of 2 cycles (21 days per cycle) of treatment in the absence of disease progression or unacceptable toxicities","title":"Response Rate (CR + PR)","type":"SECONDARY","unitOfMeasure":"Proportion of Participants"}